Replies to post #243038 on Avid Bioservices Inc (CDMO)

[md1225]

Opdivo did well in less then twenty percent of patients ie "responders" pd1 positive patients 20 months.
Bavituximab will make all patients responders . I believe we see complete responses in the durvolumab trial when combined with Bavituximab . Cancer will be seen as a chronic disease not a death sentence .

[sunstar]

Thanks Chris, thats"s a very important point. EOM

[InternetForumUser]

MD - Do you have the date as to when BMS announced that Checkmate 057 was fully enrolled? I was unable to find any information on their news releases.

Checking the Clinical Trials site, Checkmate 057 changed to Active Not Recruiting on 11/27/2013 but then again I could have read the information incorrectly.

CHECKMATE 057
Estimated Enrollment: 574
Study Start Date: October 2012
Estimated Study Completion Date: May 2016
Primary Completion Date: February 2015

EARLY STOP DUE TO EFFICACY: April, 17, 2015 (~2 Years 6 Months)

SUNRISE
Estimated Enrollment: 582
Study Start Date: December 2013
Estimated Primary Completion Date: December 2016

If CHECKMATE 057 timeline was used, then maybe June 2016 for EARLY STOP...